专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US08546539B2 Fc receptor-binding polypeptides with modified effector functions 有权
标题翻译：具有修饰的效应子功能的Fc受体结合多肽
公开(公告)号：US08546539B2
公开(公告)日：2013-10-01
申请号：US12152395
申请日：2008-05-14
申请人： Greg Elson , Olivier Leger
发明人： Greg Elson , Olivier Leger
IPC分类号： C07K16/00 , C12P21/08 , C07K1/00
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/52 , C07K2317/71
摘要： Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having modified binding characteristics for human Fc gamma receptor IIA (CD32A) leading to increased inhibition of proinflammatory mediators while retaining binding to a target antigen via its Fv portion, which processes comprise altering the polypeptides by substitution of at least two amino acid residues at EU position 325, 326 or 328 of a human IgG CH2 region for a sequence selected from SAAF, SKAF, NAAF and NKAF. Also disclosed are molecules, particularly polypeptides, more particularly immunoglobulins (e.g. antibodies) that include a variant CDR3 region, wherein the variant CDR3 region includes at least one amino acid modified relative to a wild-type CDR3 region. The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.
摘要翻译：公开了用于产生具有修饰的人Fcγ受体IIA（CD32A）结合特征的变体多肽（例如抗体）的方法，导致促炎介质的增加的抑制，同时通过其Fv部分保留与靶抗原的结合，该方法包括改变多肽通过取代选自SAAF，SKAF，NAAF和NKAF的序列的人IgG CH2区域的EU位置325,326或328处的至少两个氨基酸残基。还公开了分子，特别是多肽，更特别是包括变体CDR3区的免疫球蛋白（例如抗体），其中变体CDR3区包括相对于野生型CDR3区修饰的至少一个氨基酸。可以根据本发明的方法产生的多肽是高度可变的，并且它们可以包括含有Fc区或其生物活性部分的抗体和融合蛋白。

22. 发明申请

US20120142098A1 Fc receptor-binding polypeptides with modified effector functions 有权
标题翻译：具有修饰的效应子功能的Fc受体结合多肽
公开(公告)号：US20120142098A1
公开(公告)日：2012-06-07
申请号：US12152395
申请日：2008-05-14
申请人： Greg Elson , Olivier Leger
发明人： Greg Elson , Olivier Leger
IPC分类号： C12N5/071 , C07K19/00 , C07K16/28
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/52 , C07K2317/71
摘要： Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having modified binding characteristics for human Fc gamma receptor IIA (CD32A) leading to increased inhibition of proinflammatory mediators while retaining binding to a target antigen via its Fv portion, which processes comprise altering the polypeptides by substitution of at least two amino acid residues at EU position 325, 326 or 328 of a human IgG CH2 region for a sequence selected from SAAF, SKAF, NAAF and NKAF. Also disclosed are molecules, particularly polypeptides, more particularly immunoglobulins (e.g. antibodies) that include a variant CDR3 region, wherein the variant CDR3 region includes at least one amino acid modified relative to a wild-type CDR3 region. The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.
摘要翻译：公开了用于产生具有修饰的人Fcγ受体IIA（CD32A）结合特征的变体多肽（例如抗体）的方法，导致促炎介质的增加的抑制，同时通过其Fv部分保留与靶抗原的结合，该方法包括改变多肽通过取代选自SAAF，SKAF，NAAF和NKAF的序列的人IgG CH2区域的EU位置325,326或328处的至少两个氨基酸残基。还公开了分子，特别是多肽，更特别是包括变体CDR3区的免疫球蛋白（例如抗体），其中变体CDR3区包括相对于野生型CDR3区修饰的至少一个氨基酸。可以根据本发明的方法产生的多肽是高度可变的，并且它们可以包括含有Fc区或其生物活性部分的抗体和融合蛋白。

23. 发明申请

US20080050366A1 Neutralizing antibodies and methods of use thereof 有权
标题翻译：中和抗体及其使用方法
公开(公告)号：US20080050366A1
公开(公告)日：2008-02-28
申请号：US11151916
申请日：2005-06-14
申请人： Greg Elson , Olivier Leger
发明人： Greg Elson , Olivier Leger
IPC分类号： A61K39/00 , C07K16/00 , C12P21/08
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
摘要翻译：本发明提供识别Toll样受体4 / MD-2受体复合物的单克隆抗体，以及当与MD-2不复合时识别TLR4 / MD2复合物以及TLR4的单克隆抗体。本发明还提供使用人源化单克隆抗体作为治疗剂的方法。本发明还提供可溶性嵌合蛋白，表达和纯化可溶性嵌合蛋白的方法，以及在筛选测定和抗体生成中使用可溶性嵌合蛋白作为治疗剂的方法。

24. 发明授权

US08609822B2 Neutralizing antibodies and methods of use thereof 有权
标题翻译：中和抗体及其使用方法
公开(公告)号：US08609822B2
公开(公告)日：2013-12-17
申请号：US13362974
申请日：2012-01-31
申请人： Greg Elson , Olivier Leger
发明人： Greg Elson , Olivier Leger
IPC分类号： C07K16/00 , C07K17/00
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
摘要翻译：本发明提供识别Toll样受体4 / MD-2受体复合物的单克隆抗体，以及当与MD-2不复合时识别TLR4 / MD2复合物以及TLR4的单克隆抗体。本发明还提供使用人源化单克隆抗体作为治疗剂的方法。本发明还提供可溶性嵌合蛋白，表达和纯化可溶性嵌合蛋白的方法，以及在筛选测定和抗体生成中使用可溶性嵌合蛋白作为治疗剂的方法。

25. 发明授权

US08105595B2 Methods of using neutralizing anti-TLR4/MD2 antibodies 有权
标题翻译：使用中和抗TLR4 / MD2抗体的方法
公开(公告)号：US08105595B2
公开(公告)日：2012-01-31
申请号：US12719561
申请日：2010-03-08
申请人： Greg Elson , Olivier Leger
发明人： Greg Elson , Olivier Leger
IPC分类号： A61K39/395 , C07K16/00 , C12P21/08
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
摘要翻译：本发明提供识别Toll样受体4 / MD-2受体复合物的单克隆抗体，以及当与MD-2不复合时识别TLR4 / MD2复合物和TLR4的单克隆抗体。本发明还提供使用人源化单克隆抗体作为治疗剂的方法。本发明还提供可溶性嵌合蛋白，表达和纯化可溶性嵌合蛋白的方法，以及在筛选测定和抗体生成中使用可溶性嵌合蛋白作为治疗剂的方法。

26. 发明授权

US07674884B2 Neutralizing antibodies and methods of use thereof 有权
标题翻译：中和抗体及其使用方法
公开(公告)号：US07674884B2
公开(公告)日：2010-03-09
申请号：US11151916
申请日：2005-06-14
申请人： Greg Elson , Olivier Leger
发明人： Greg Elson , Olivier Leger
IPC分类号： C12P21/08 , C07K16/00 , A61K39/395 , A61K39/00
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
摘要翻译：本发明提供识别Toll样受体4 / MD-2受体复合物的单克隆抗体，以及当与MD-2不复合时识别TLR4 / MD2复合物以及TLR4的单克隆抗体。本发明还提供使用人源化单克隆抗体作为治疗剂的方法。本发明还提供可溶性嵌合蛋白，表达和纯化可溶性嵌合蛋白的方法，以及在筛选测定和抗体生成中使用可溶性嵌合蛋白作为治疗剂的方法。

27. 发明申请

US20120148593A1 Neutralizing Antibodies And Methods Of Use Thereof 有权
标题翻译：中和抗体及其使用方法
公开(公告)号：US20120148593A1
公开(公告)日：2012-06-14
申请号：US13362974
申请日：2012-01-31
申请人： Greg Elson , Olivier Leger
发明人： Greg Elson , Olivier Leger
IPC分类号： A61K39/395 , A61P29/00 , A61P11/00 , A61P19/02 , A61P11/06 , A61P37/08 , A61P9/10 , A61P1/00 , C07K16/28 , A61P37/06
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
摘要翻译：本发明提供识别Toll样受体4 / MD-2受体复合物的单克隆抗体，以及当与MD-2不复合时识别TLR4 / MD2复合物以及TLR4的单克隆抗体。本发明还提供使用人源化单克隆抗体作为治疗剂的方法。本发明还提供可溶性嵌合蛋白，表达和纯化可溶性嵌合蛋白的方法，以及在筛选测定和抗体生成中使用可溶性嵌合蛋白作为治疗剂的方法。

28. 发明授权

US08029794B2 Combining therapies targeting multiple toll-like receptors 有权
标题翻译：结合靶向多个toll样受体的疗法
公开(公告)号：US08029794B2
公开(公告)日：2011-10-04
申请号：US11301373
申请日：2005-12-12
申请人： Greg Elson , Olivier Leger
发明人： Greg Elson , Olivier Leger
IPC分类号： A61K39/395
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/76
摘要： The invention relates generally to compositions that contain multiple antibodies, e.g., multiple neutralizing antibodies, that immunospecifically bind to one or more toll-like receptors, e.g., two or more toll-like receptors, and methods of using these compositions in the treatment of inflammatory disorders.
摘要翻译：本发明一般涉及包含多种抗体的组合物，例如多种中和抗体，其免疫特异性结合一种或多种toll样受体，例如两种或多种toll样受体，以及使用这些组合物治疗炎症的方法疾病

29. 发明申请

US20060165686A1 Combining therapies targeting multiple toll-like receptors and use thereof 有权
标题翻译：组合靶向多个toll样受体的疗法及其用途
公开(公告)号：US20060165686A1
公开(公告)日：2006-07-27
申请号：US11301373
申请日：2005-12-12
申请人： Greg Elson , Olivier Leger
发明人： Greg Elson , Olivier Leger
IPC分类号： A61K39/395
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/76
摘要： The invention relates generally to compositions that contain multiple antibodies, e.g., multiple neutralizing antibodies, that immunospecifically bind to one or more toll-like receptors, e.g., two or more toll-like receptors, and methods of using these compositions in the treatment of inflammatory disorders.
摘要翻译：本发明一般涉及包含多种抗体的组合物，例如多种中和抗体，其免疫特异性结合一种或多种toll样受体，例如两种或多种toll样受体，以及使用这些组合物治疗炎症的方法疾病

30. 发明授权

US08808999B2 Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof 有权
标题翻译：抗IGF-1R和/或抗胰岛素/ IGF-I杂合受体抗体及其用途
公开(公告)号：US08808999B2
公开(公告)日：2014-08-19
申请号：US13352599
申请日：2012-01-18
申请人： Liliane Goetsch , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
IPC分类号： C07K14/72 , C07K16/28
CPC分类号： A61K47/6805 , C07K2317/732
摘要： The present invention relates to methods of identifying IGF-IR modulators and hybrid-R modulators comprising contacting IGF-IR with a humanized anti-IGF-IR antibody and contacting hybrid-R with a humanized anti-hybrid-R antibody, respectively.
摘要翻译：本发明涉及鉴定IGF-1R调节剂和杂合-R调节剂的方法，其包括将IGF-1R与人源化抗IGF-1R抗体接触并分别使杂交-R与人源化抗混合-R抗体接触。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式